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We encapsulated cyclosporine A (CsA) in poly(ethylene glycol)-b-poly(d,l-lactide-co-glycolide) (PEG-PLGA) nanoparticles (NPs)
by nanoprecipitation of CsA and PEG-PLGA. The resulting CsA/PEG-PLGA-NPs were <100 nm in diameter with a narrow
particle size distribution. The NP size could be controlled by tuning the polymer concentration, solvent, or water/solvent ratio
during formulation. The PEGylated NPs maintained non-aggregated in salt solution. Solid NPs lyoprotected with bovine serum
albumin were prepared for the convenience of storage and transportation. The release kinetics of CsA (55.6% released on Day 1)
showed potential for maintaining therapeutic CsA concentrations in vivo. In T-cell assays, both free CsA and CsA/PEG-PLGA-NPs
suppressed T-cell proliferation and production of inflammatory cytokines dose dependently. In amixed lymphocyte reaction assay,
the IC50 values for free CsA and CsA/PEG-PLGA-NPs were found to be 30 and 35 ng/mL, respectively. This nanoparticulate CsA
delivery technology constitutes a strong basis for future targeted delivery of immunosuppressive drugs with improved eﬃciency
and potentially reduced toxicity.
1. Introduction
The eﬃcacy of immunosuppressive drugs has markedly im-
proved over the last 2 decades, and as a result, the 1-year
graft survival rate now exceeds 80% for most solid organ
transplant. However, only modest improvements of long-
term graft survival rates have been achieved, owing mainly
to the systemic toxicity of immunosuppressants. When cal-
cin-eurin inhibitors were introduced in mid-1980s, they
revolutionized the field of transplantation by substantially
reducing the rate of acute rejection [1, 2]. In particular, the
discovery of cyclosporine A (CsA), a highly lipophilic neutral
cyclic peptide, was a milestone in organ transplantation and
the treatment of autoimmune diseases.
CsA eﬀectively suppresses immune reactions dependency
on T cells, which are the key eﬀector cells involved in graft
rejection and autoimmunity. It forms a complex with cyclo-
philin, a cytoplasmic receptor protein present in T lympho-
cytes, and this complex then binds to calcineurin and in-
hibits Ca2+-stimulated dephosphorylation of the cytoplasmic
component of the nuclear factor of activated T cells. This
factor regulates transcription of numerous genes involved
in T-cell activation and proliferation, such as IL-2, L-4, and
CD40 ligand [14]. When these genes are not ex-pressed, T-
cell-dependent immune responses are dramatically inhib-
ited. However, CsA exhibits low oral bioavailability owing to
its poor biopharmaceutical properties, such as its high mo-
lecular weight (1202Da), low solubility, low permeability,
and high presystemic metabolism [3, 4]. Consequently, there
is an urgent need for the design and development of a novel
formulation of CsA with better bioavailability and fewer side
eﬀects.
Nanotechnology has been increasingly used in medicine
[5]. For example, nanoparticulate formulations of drugs
can extend their blood circulation and oﬀer new methods
for targeted drug delivery after intravenous administration.
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Several nanoparticulate CsA formulations, such as emul-
sions, liposomes, microspheres, and polymeric nanoparticles
(NPs), have been developed to compensate for the poor bio-
pharmaceutical properties of CsA and potentially reduce its
side eﬀects through specific targeting and controlled release
of CsA [6, 7]. In particular, polymeric NPs based on
polylactide (PLA) or poly(lactide-co-glycolide) (PLGA) have
attracted much attention as delivery vehicles for CsA because
of their excellent biocompatibility [8–11]. The nanopartic-
ulate formulations developed to date have improved the
overall bioavailability of CsA and protected the milieu which
surrounds the disease site from the toxicity of CsA. Many of
the published studies have focused on controlling the for-
mulation for maintaining therapeutic blood levels of CsA or
for achieving favorable biodistribution. However, if clinically
relevant NP-encapsulated CsA are to be developed success-
fully, their immunosuppressive capability must be directly
demonstrated and assessed.
In a recent report, we described a novel formulation of
CsA-PLA covalently conjugated with NPs for targeted immu-
nosuppression [12]. This new formulation suppresses T-cell
proliferation both in vitro and in vivo and shows reduced
organ toxicity. However, the release of CsA from the pol-
ymeric NPs is relatively slow (only ∼20% of the CsA is
released over 2 weeks). Therefore, maintenance of CsA con-
centrations within the therapeutic window after intrave-
nous administration is diﬃcult with this formulation. In an
attempt to increase the eﬀective concentration of CsA de-
livered by the NPs, we encapsulated CsA in size-controlled
poly(ethylene glycol)-b-poly(d,l-lactide-co-glycolide) (PEG-
PLGA) NPs instead of using the covalent conjugation strate-
gy. Owing to the absence of covalent bonds between CsA and
the polymer matrix, we expected this encapsulation strategy
to permit more eﬀective release of CsA to achieve the desired
CsA concentration. In the meantime, the controlled release
of CsA can reduce the Cmax of CsA while keeping the same
AUC [13].
To demonstrate and assess the immunosuppressive activ-
ity of CsA-containing PEG-PLGA NPs, we designed several
in vitro assays to directly evaluate the capacity of this formu-
lation to suppress the activation and proliferation of T cells
in vitro. We also investigated the control of NP sizes of the
CsA-containing PEG-PLGA NPs. Because the immunosup-
pressive activity of CsA is related to its selective action against
T lymphocytes, which circulate mainly in the lymphatic sys-
tem, eﬀective targeting of the lymphatic system is clearly
important for the delivery of CsA. Some recent reports have
emphasized that smaller NPs more eﬀectively target the lym-
phatic system [15, 16]. Moreover, smaller NPs may also min-
imize the burst release of CsA from NPs [11]. However,
size control of NP delivery systems for CsA has been rarely
reported. Recently, we used PEG-PLGA to formulate size-
controlled NPs for delivery of anticancer drugs [17]. Owing
to the facile formulation procedure and excellent control over
NP size, we applied similar techniques in this study to obtain
size-controlled PEG-PLGA NPs encapsulating CsA. These
PEG-PLGA NPs encapsulating CsA were stable in biological
media with negligible aggregation. To ensure the potential
clinical translation, NPs in solid form with unchanged prop-
erties is preferred. In this study, we tested and demonstrated
that solid form of CsA/PEG-PLGA NP can be prepared by
using bovine serum albumin (BSA) as a lyoprotectant.
2. Materials and Methods
2.1. General. Cyclosporine A (LC Laboratories, Woburn,
MA, USA) was used as received. All other chemicals were
obtained from Sigma-Aldrich (St. Louis, MO) unless other-
wise noted. Poly(ethylene glycol)-b-poly(d,l-lactide-co-gly-
colide) was purchased from Laysan Bio (Arab, AL, USA). All
anhydrous solvents were passed through alumina columns
and kept anhydrous over molecular sieves. HPLC analysis
was performed on a System Gold system (Beckman Coulter,
Fullerton, CA, USA) equipped with a 126P solvent module
(Beckman), a System Gold 128 UV detector (Beckman), and
an analytical column (Jupiter, 250 × 4.6mm, 5 μm, Phenom-
enex, Torrence, CA, USA). The UV wavelength used for de-
tection was 207 nm. The size and size dispersity of nano-
particles were characterized on Hitachi S4800 high-resolu-
tion scanning electron microscope (SEM). NP sizes and dis-
persities were also monitored in real time with a Zeta PALS
dynamic light-scattering (DLS) detector (15mW laser, inci-
dent beam = 676 nm, Brookhaven Instruments, Holtsville,
NY, USA). NPs were lyophilized on a benchtop lyophilizer
(Freezone 2.5, Fisher Scientific, Pittsburgh, PA, USA).
2.2. Preparation of CsA-Containing PEG-PLGA NPs (CsA/
PEG-PLGA-NPs). The average molecular weight and pol-
ydispersity of PEG-PLGA were 16,400 g/mol and 1.19, re-
spectively, as determined by size-exclusion chromatography
coupled to an Optilab rEX refractive index detector and
a DAWN HELEOS 18-angle laser light scattering detector
(MALLS, Optilab rEX refractive index detector). A nano-
precipitation method was used to formulate CsA-containing
PEG-PLGA NPs. Briefly, PEG-PLGA (157.3mg) was added
to an acetone solution of CsA (4.9mg, 0.004mmol) to make
the concentration of PEG-PLGA 10mg/mL. This solution
(1.0mL) was added dropwise into 20mL nanopure water
under vigorous stirring to formulate CsA-encapsulated PEG-
PLGA NPs. The NP suspension was stirred uncovered for 6 h
at room temperature in a chemical hood in order to com-
pletely evaporate the organic solvent. An aliquot of the NP
suspension was centrifuged (10min, 10 k rpm) and the su-
pernatant was analyzed by a reverse-phase HPLC to quantify
the unencapsulated CsA in order to determine the incorpo-
ration eﬃciency and loading of CsA in PEG-PLGA NPs. The
NPs were purified and collected by ultrafiltration (15min,
3000 rpm, Amicon Ultra, Ultracel membrane with 100,000
NMWL, Millipore, Billerica, MA, USA) and lyophilized. The
size and polydispersity of the resulting NPs were determined
by DLS and SEM.
2.3. Size Control of CsA/PEG-PLGA-NPs. Parameters con-
trolling formulation of the NPs were systematically varied in
this study. The nanoprecipitation method was employed for
the formation of CsA-encapsulated PEG-PLGA NPs. Gen-
erally, the starting formulation was as follows: PEG-PLGA
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(10mg/mL) and CsA (0.31mg/mL) were dissolved in N,N-
dimethylformamide (DMF). The mixture was added drop-
wise to a 20-fold volume of vigorously stirred nanopure
water. The NPs were produced with the nanoprecipitation
method in a water-miscible solvent, such as: DMF, acetone,
and tetrahydrofuran (THF). The eﬀects of the various sol-
vents were assayed on the overall size of the NPs. For each sol-
vent, a range of polymer concentrations in the organic phase
from 1mg/mL to 10mg/mL was used for the formation of
the NPs in a 20-fold volume of water. Then, polymer con-
centration was fixed at 10mg/mL; the eﬀect of volume ratio
of water/organic solvent (5/1, 10/1, 20/1, 40/1) was studied.
2.4. Stability of CsA/PEG-PLGA-NPs in Salt Solution. The
postformulation stability of NPs in PBS (1×) was studied
for both poly(ethyleneglycol)ated (PEGylated) and non-
PEGylated NPs. PEGylated NPs were formed by precipitating
100 μL of a DMF solution of PEG-PLGA (10mg/mL) and
CsA (0.31mg/mL) to DI water (2mL) under vigorous stir-
ring. For non-PEGylated NPs, 100 μL of a DMF solution of
PLGA (10mg/mL) and CsA (0.31mg/mL) was used instead.
Afterwards, 10× PBS solution was added to bring the whole
mixture to 1× PBS. The NP sizes in PBS were measured by
DLS and followed over 30min.
2.5. Lyophilization of CsA/PEG-PLGA-NPs in the Presence of
BSA as a Lyoprotectant. Bovine serum albumin (BSA) as a ly-
oprotectant was added to the concentrated NP suspension at
a BSA/NP mass ratio of 10/1. The solution was then lyophil-
ized to dry powder, which was stored at −20◦C prior to use.
The NPs were reconstituted with water and stirred for 5min.
The sizes of the resulting NPs were analyzed by DLS.
2.6. Determination of the Release Kinetics of CsA/PEG-PLGA-
NPs. The solution of CsA/PEG-PLGA-NPs (0.43mg/mL)
was incubated in 1× PBS at 37◦C. At scheduled time intervals
(t = 0, 1, 2, 3, and 4 days), the incubated NP solutions were
taken out and lyophilized overnight to dry. Ether was added
to extract all the released CsA. After the solvent was evap-
orated, 500 μL acetonitrile (ACN) was added. This solution
was analyzed by HPLC to quantify the released CsA. The
release kinetics of CsA was determined by comparing the
released CsA versus the total CsA, which was calculated by
the loading information.
2.7. Mixed Lymphocyte Reaction and CD3/CD28 T-Cell Stim-
ulation Assays. The mixed lymphocyte reaction (MLR) assay
was performed as described previously [18]. Briefly, in 96-
well U-bottom plates, 5 × 105 each of responder and irra-
diated stimulator splenocytes were cultured in triplicates in
the presence of increasing dosages of free CsA and CsA/PEG-
PLGA-NPs (free CsA and CsA/PEG-PLGA-NPs were added
at the same equivalent dosage of CsA) for 48 hours. Another
group of PEG-PLGA-NPs without CsA was added at the
same total mass concentration of NP as negative control.
Cultures were pulsed with 1 μCi of triturated thymidine
and the incorporation eﬃciencies were determined. Data are
expressed as the mean cpm of the [H] thymidine uptake by
triplicate cultures plus the standard deviation. For the CD3/
CD28 stimulation assay, 100 μL of anti-CD3 antibody in PBS
(1 ug/mL, eBioscience, San Diego, CA, USA) was added to
each well of a 96-well flat bottom plate, incubated at 37◦C
for 4 hours, and then washed twice with PBS. Soluble anti-
CD28 antibody (1 μg/mL, eBioscience) was added to each
well in the presence of 5 × 105 responder splenocytes and an
increasing concentration of free CsA, CsA/PEG-PLGA-NPs,
and PEG-PLGA-NPs. Cultures were pulsed with triturated
thymidine as described above.
2.8. ELISpot Assay. The enzyme-linked immunosorbent spot
(ELISpot) was performed as previously described by us [19].
Briefly, ELISpot plates were coated with capture antibodies
against interferon (IFN-γ). A total of 5 × 105 splenocytes
were cultured in triplicate in the presence of the same num-
ber of irradiated allogeneic splenocytes. Irradiated syngeneic
splenocytes and Con A were used as negative and positive
controls, respectively. Diﬀerent concentrations of free CsA,
CsA/PEG-PLGA-NPs, and PEG-PLGA-NPs were added to
the wells. After 48 hours, the resulting spots were counted
on a computer-assisted ELISAspot image analyzer (Cellular
Technology).
3. Results
3.1. Preparation of CsA/PEG-PLGA-NPs. When CsA was
mixed with the amphiphilic block polymer PEG-PLGA in an
organic solvent, and the mixture was added dropwise to a
nonsolvent (e.g., water), the hydrophobic domain of PEG-
PLGA (PLGA) formed a hydrophobic core with CsA being
encapsulated (Figure 1(a)). The hydrophilic domain, PEG,
remained on the surface of the polymeric NPs and stabilized
the NP size. The diameter of the prepared CsA/PEG-PLGA-
NPs was 83.3 ± 0.8 nm with a monomodal particle size dis-
tribution and low polydispersity (Figure 1(b)). The narrow,
monomodal particle size distribution was confirmed by SEM
analysis (Figure 1(c)). Spherical sub-100-nm NPs could be
seen clearly by SEM. The CsA loading was determined to be
3.3% (w/w) by HPLC.
3.2. Control of the Size of the CsA/PEG-PLGA-NPs Prepared
via Nanoprecipitation. When the PEG-PLGA concentration
was varied during NP preparation at a fixed water/solvent
ratio of 20/1 (Figure 2(a)), NP size increased linearly with
increasing polymer concentration (R2 = 0.995 in DMF). Spe-
cifically, the NP size increased from 50.3 to 83.9 nm in DMF
as the polymer concentration was increased 10 folds (from 1
to 10mg/mL). Similar trends were observed in acetone (R2 =
0.994) and in THF (R2 = 0.999). The NPs formulated with
THF were larger than those formulated with either DMF or
acetone at the same polymer concentration.
The water miscibility of the organic solvent also aﬀected
the size of the NPs [17, 20, 21]. Increasing the water misci-
bility led to a decrease in the mean NP size when all other
formulation parameters were held constant. NPs prepared
in THF, the least water-miscible of the tested solvents, had
the largest particle size (Figure 2(a)). Because acetone, unlike
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Figure 1: (a) Preparation of CsA/PEG-PLGA-NPs through nanoprecipitation. DLS (b) and SEM (c) characterization of the sizes of the
CsA/PEG-PLGA-NPs.
DMF, can be easily removed by evaporation and the NPs
prepared with acetone were comparable in size to the NPs
prepared with DMF, we used acetone as the solvent for
CsA and PEG-PLGA in the nanoprecipitation of CsA/PEG-
PLGA-NPs.
At a fixed polymer concentration of 10mg/mL
(Figure 2(b)), the NP size decreased with increasing water/
solvent ratio: for example, NP size decreased from 117.7 to
79.4 nm when the water/DMF ratio was increased from 5/1
to 40/1. In comparison, the NP sizes were 134.9 and 95.6 nm
when the water/THF ratios were 5/1 and 40/1, respectively.
For both solvents, when the water/solvent ratio was de-
creased from 10/1 to 5/1, a large increase in NP size (∼20–
30 nm) was observed.
3.3. Stability of CsA/PEG-PLGA-NPs in Salt Solution. Poly-
meric NPs tend to aggregate under biological conditions. To
achieve prolonged systemic circulation and disease targeting,
NPs should remain nonaggregated under physiological con-
ditions. One method for preventing aggregation is to modify
NP surfaces with PEG (PEGylation) [17, 22, 23]. To mimic
the behavior of the NPs under physiological conditions, we
evaluated NP stability in PBS. After precipitating a DMF
solution of CsA and PEG-PLGA in vigorously stirred DI wa-
ter and subsequently tuning the solution to 1× PBS, the NPs
remained nonaggregated for at least 30min, evidenced by
the DLS analyses (Figure 2(c)). In contrast, non-PEGylated
NPs (CsA-containing PLGA NPs) rapidly formed aggregates
in PBS (Figure 2(c)); the particle size increased from 108 nm
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Figure 2: Controlled formulation of CsA/PEG-PLGA-NPs. Correlation of NP sizes versus polymer concentrations in diﬀerent organic sol-
vents at constant ratio of volume of solvent to water. NP sizes increased from 42.3 nm to 91.4 nm as the polymer concentration increased
from 1mg/mL to 10mg/mL in DMF. Similar trends were observed in acetone and THF (a). Correlation of NP sizes versus ratio of volume of
solvent to water in diﬀerent organic solvents at constant polymer concentrations (10mg/mL) (b). The PEGylated CsA/PEG-PLGA-NPs kept
their original size and remained nonaggregated for an extended period of time. However, when the non-PEGylated NPs were tested in PBS
(1×), they were unstable and formed large aggregates rapidly (the particle size increased from 108.1 nm to 3223.1 nm within 1min) (c). The
size of NPs increased slightly but maintained a single distribution after lyophilization with BSA as the lyoprotectant (d).
to over 3 μmwithin 1min. The enhanced stability of the CsA/
PEG-PLGA-NPs in PBS suggests that they may show long
circulation profile in vivo.
3.4. Control of NP Size during Postformulation Treatment.
The stability of any biodegradable formulation upon storage
is a concern for clinical use. Freeze drying NPs and then stor-
ing them in the solid state is a common approach for main-
taining stability. We previously reported that albumin is an
excellent lyoprotectant for the preparation of NPs in solid
form, allowing lyophilized NPs to be readily dispersed in
PBS (1×) without noticeable formation of aggregates [24].
In this study, the addition of a 10-fold excess mass of BSA
to an aqueous suspension of CsA/PEG-PLGA-NPs resulted
in recovery of NPs that were slightly larger than the original
NPs (Figure 2(d)); these NPs which are in solid form could
be readily dispersed in PBS (1×) without any aggregation.
Without BSA as a lyoprotectant, the NPs formed aggregates
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that were several to tens of micrometers in size (data not
shown) and could not be redispersed in PBS (1×). Thus,
they were not useful upon reconstitution for in vivo systemic
delivery.
3.5. Determination of CsA/PEG-PLGA-NPs Release Kinetics.
We recently reported that CsA release from CsA-PLA con-
jugated NPs (8.0 wt%) proceeds in a controlled but slow
fashion, with 14.1% being released by Day 4 and 21.0% by
Day 14 [12]. For this CsA-encapsulated PEG-PLGA NPs,
CsA release was much faster compared to CsA release from
the conjugated NPs because CsA was physically encapsulated
inside the polymeric NPs without any covalent bonding. Up
to 70% of CsA was released by Day 2 (Figure 3).
3.6. Suppression of T-Cell Proliferation by CsA/PEG-PLGA-
NPs. To compare the immunosuppressive abilities of CsA/
PEG-PLGA-NPs and free CsA in an in vitro model relevant
to transplantation, we added CsA/PEG-PLGA-NPs, free CsA,
and PEG-PLGA-NPs at various concentrations to an MLR
assay system. As compared to the positive control, free CsA
dose dependently inhibited splenocyte proliferation in the
MLR assay. The same pattern of suppression was observed
for CsA/PEG-PLGA-NPs (Figures 4(a) and 4(d)). In contrast,
equivalent concentrations of PEG-PLGA NPs did not sup-
press T-cell proliferation (data not shown).
We also evaluated the immunosuppressive eﬀects of the
NPs by means of a CD3-CD28 stimulation assay, which has
traditionally been used to test the immunosuppressive effects
of newly introduced drugs for the treatment of various im-
mune-mediated diseases [25]. The results of the CD3-CD28
assay were similar to those of the MLR assay: CsA/PEG-
PLGA-NPs dose dependently suppressed T-cell proliferation
similar to free CsA (Figure 4(b)). The IC50 values for free
CsA and CsA/PEG-PLGA-NPs, calculated from the sup-
pression of T-cell proliferation in the MLR assay, were 30
and 35 ng/mL, respectively (Figure 4(d)). The higher IC50 of
CsA/PEG-PLGA-NPs is consistent with the controlled release
of CsA/PEG-PLGA-NPs. PEG-PLGA NPs had no eﬀect on
cytokine production (data not shown).
3.7. Suppression of Inflammatory Cytokine Production by
CsA/PEG-PLGA-NPs. In addition to testing the eﬀects of the
NPs on T-cell proliferation, we also tested their eﬀects on the
pattern of IFN-γ production by activated T cells, which plays
an important role in the pathogenesis of T-cell-mediated
diseases [26–28]. The frequency of IFN-γ-producing cells
was measured by means of an ELISpot assay with cultured
splenocytes of C57Bl/6 mice in response to stimulation by
irradiated BALB/c splenocytes in vitro in the presence of
increasing doses of either free CsA or CsA/PEG-PLGA-NPs
(Figure 4(c)). ELISpot is a sensitive, highly repr ducible assay
for measuring IFN-γ production, and is often used to exam-
ine alloreactive T-cell priming in the context of transplanta-
tion. All assays showed significant response to concanavalin
A, indicating adequate viability of these cells. The number
of spots in the wells with syngeneic splenocytes was used as
the negative control. In all cases, the number of background
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Figure 3: The release profile of CsA from CsA/PEG-PLGA-NPs in
PBS (1×) at 37◦C.
spots was considered when analyzing the data. As compared
to the positive control (untreated stimulated cells), both
free CsA and CsA/PEG-PLGA-NPs comparably reduced the
frequency of IFN-γ-producing cells in a concentration-de-
pendentmanner starting at 10 ng/mL (Figure 4(c); P < 0.05).
No suppression was observed with PEG-PLGA-NPs.
4. Discussion
Nanoprecipitation is extensively used for the preparation of
NPs with therapeutic agents embedded in the hydrophobic
polymeric matrices. This method allows for rapid access to
NPs in large quantities [17]. Typically, a mixture of a hydro-
phobic polymer and the drug is dissolved in a water-miscible
organic solvent (e.g., DMF or acetone), and then the solution
is added dropwise to a vigorously stirred water solution. In-
stantaneous diﬀusion of the organic solvent into the water
results in the formation of polymeric NPs containing the
drug. Optimization of the properties of the drug and pol-
ymer is important for eﬃcient encapsulation of the drug.
CsA, which is highly lipophilic, is suitable for incorporation
into a hydrophobic polymer matrix to form CsA-containing
polymeric NPs by means of nanoprecipitation. In this study,
we used nanoprecipitation to prepare CsA-containing PEG-
PLGANPs and found that the hydrophobic polymer segment
(i.e., PLGA) shielded the drug from the external environ-
ment, thus limiting its toxicity and allowing its coupling to
targeted cellular therapy.
Particle size is one of the most important parameters
of NPs and strongly influences their biodistribution, clear-
ance kinetics, and in vivo eﬃcacy [29–31]. The development
of strategies for precisely controlling particle size is of inter-
est for both basic research and clinical applications. Here,
we were able to control the size of CsA/PEG-PLGA-NPs
by tuning the polymer concentration, solvent, or water/sol-
vent ratio during the formulation process. Previous studies
by others [20, 32] and by us [17] have suggested that the
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Figure 4: The CsA/PEG-PLGA-NPs suppress T-cell activation in MLR, CD3-CD28, and ELISpot assays. (a) CsA/PEG-PLGA-NPs showed
dose-dependent inhibition of T-cell proliferation in an MLR assay starting at 10 ng/mL equivalent concentration of CsA. (b) CsA/PEG-
PLGA-NPs suppressed T-cell proliferation in a CD3-CD28 stimulation assay in a dose-dependent manner starting at 10 ng/mL. PEG-PLGA-
NPs was unable to suppress. Data are expressed as the mean cpm of the [H] thymidine uptake by triplicate cultures and represented by the
y axis. The diﬀerent concentrations used are represented by the x axis (∗P < 0.05). Data are representative of two separate experiments. (c)
The incidence of cells producing IFN-γ was first measured by ELISpot assay from cultured splenocytes of C57Bl/6 animals responding to
BALB/c stimulating splenocytes in vitro. As compared to the positive control (untreated stimulated cells), CsA-NPs reduced the frequency of
IFN-γ-producing cells in a concentration-dependent manner (∗P < 0.05). Data are representative of two separate experiments (∗P < 0.05).
(d) IC50 calculation using the percentage of cell proliferation in a MLR assay, measured by thymidine uptake in response to increasing dose
of free CsA and CsA equivalent of CsA/PEG-PLGA-NPs (∗P < 0.05).
miscibility of the organic solvent in water aﬀects NP size in
a given solvent/water system. Generally, the miscibility can
be quantitatively expressed by comparing the solubility pa-
rameters (δ) of both the solvent and water [33]. As shown
in Figure 2(a), the size of the CsA/PEG-PLGA-NPs and the
water miscibility of the organic solvents used in this study
were inversely correlated: an increase in the water miscibility
(a decrease in the diﬀerence of solvents’ solubility parameter
Δδ) led to a decrease in the mean size of the NPs when all the
other formulation parameters were held constant. Smaller
NPs were prepared in DMF or acetone than THF because
they are more water miscible than THF and thus have more
eﬃcient solvent diﬀusion and polymer dispersion into water.
In a recent paper, we reported the CsA-release kinetics
of CsA-PLA conjugated NPs [12]. Because CsA release from
the conjugated NPs involves not only diﬀusion but also
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hydrolysis of the ester linker between CsA and the polymer,
CsA release from the conjugated NPs is much slower than
the encapsulated formulation. CsA is released from CsA-
PLA NPs slowly and in a controlled fashion, with 14.1%
being released by day 4 and 21.0% by day 14. In contrast,
the CsA/PEG-PLGA-NPs released CsA much more quickly,
mainly because there were no covalent bonds between CsA
and the polymer matrix and the release kinetics were con-
trolled solely by diﬀusion.
Finally, we tested the ability of the CsA/PEG-PLGA-NPs
to suppress T-cell activation in vitro. We first evaluated the
immunosuppressive eﬀects of the NPs by means of a CD3-
CD28 stimulation assay, which have traditionally been used
to test the immunosuppressive eﬀects of newly introduced
drugs for the treatment of various immune-mediated dis-
eases [25]. The released CsA inhibited T-cell proliferation in
a dose-dependent manner, not only in a CD3/CD28 assay
but also in an alloreactive MLR assay. IFN-γ production by
alloreactive T cells was also suppressed by the CsA/PEG-
PLGA-NPs in a dose-dependentmanner, and the suppression
was comparable to that observed for free CsA. Nanoparticles
injected intravenously could accumulate in tumors via the
enhanced permeability and retention (EPR) eﬀect. Our CsA/
PEG-PLGANP could be potentially used to deliver cyclospo-
rine to inflamed lymphoid tissues via the similar eﬀect [34].
NPs preferentially accumulate at target sites of inflammation
due in part to increased vascular permeability.
5. Conclusions
We formulated CsA-encapsulated PEG-PLGA NPs with con-
trolled sizes and excellent stability in PBS. When BSA was
used as the lyoprotectant, the CsA-encapsulated PEG-PLGA
NPs could be prepared in the solid form without noticeable
change of properties. CsA released from the CsA/PEG-
PLGA-NPs suppressed the proliferation of T cells and the
production of inflammatory cytokines in vitro. With the use
of this controlled release technology in conjunction with
precisely controlled particle size, this immunosuppressive
nanomedicine showed well-maintained in vitro therapeutic
efficacy. In the future work, we will evaluate the in vivo
immunosuppressive activity of the nanoformulation in a
murine transplant model to determine its potential for clinic
use.
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